Puma Biotechnology (NASDAQ:PBYI), a pharmaceutical company focused on therapies for cancer, released its second quarter 2025 earnings on August 7, 2025. The company posted non-GAAP earnings per share of $0.15, outperforming consensus non-GAAP EPS estimates of $0.09, and revenue (GAAP) of $52.4 million, topping the projected $52.0 million in GAAP revenue. This period marked a return to profitability for Puma, as it registered GAAP net income of $5.9 million after a loss in the year-ago quarter. Performance was slightly ahead of expectations, with total revenue (GAAP) up approximately 11.2% compared to Q2 2024. Management reiterated guidance for the full year, projecting total revenue (GAAP) between $212 million and $222 million and net income of $23 million to $28 million. Overall, the quarter demonstrated modest growth in product sales, with net product revenue of $49.2 million compared to $44.4 million for Q2 2024 (GAAP), effective expense controls, and steady progress on pipeline projects.

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.

Puma Biotechnology (NASDAQ:PBYI) develops and commercializes treatments for cancer, with a particular focus on breast cancer. Its core medicine is NERLYNX, an oral drug for HER2-positive breast cancer that aims to reduce the risk of disease recurrence or progression. Puma also invests in research for alisertib, an investigational treatment for specific cancer types.

Continue reading

Source Fool.com